Lambda Light Chain Antibodies

Structure of Lambda Light Chain

Lambda light chain is a protein with a molecular weight of approximately 23 kDa. Its precise molecular weight varies slightly among different species, mainly due to changes in the amino acid sequences of the constant and variable regions. The following is a comparison of the molecular weight and structural characteristics of Lambda light chains in common species:

The Lambda light chain is composed of approximately 210 amino acids, and its three-dimensional structure contains two immunoglobulin domains: the variable domain (VL) at the N-terminal and the constant domain (CL) at the C-terminal. Each domain adopts a typical immunoglobulin folding pattern, composed of two reverse-parallel β sheets stably linked by disulfide bonds. The complementary determinant (CDR) in the variable domain is responsible for antigen-specific binding, and its conformational diversity is the structural basis for the functional diversity of antibodies. Light chains and heavy chains form complete antibody molecules through disulfide bonds and hydrophobic interactions between the CL and CH1 domains.

Fig. 1 Lambda Light Chain-Restricted Hematogones: A Diagnostic Pitfall in Bone Marrow Analysis.¹

Key structural properties of Lambda Light Chain:

• Typical immunoglobulin folding structure (β -sandwich configuration)
• The variable region (VL) and the constant region (CL) are stably connected by disulfide bonds
• Complementary determinant regions (CDRS) mediate antigen-specific recognition and binding

Functions of Lambda Light Chain

The main function of Lambda light chain is to serve as an important component of antibodies, participating in immune recognition and antigen binding. In addition, it also involves the development of B cells, signal transduction and the regulation of various pathological processes.

The ratio of Lambda light chain to κ light chain in the human body is approximately 1:2. This relatively constant ratio (light chain ratio) is often used in clinical diagnosis and immunohistochemical analysis to detect B-cell clonal proliferation and related diseases.

Applications of Lambda Light Chain and Lambda Light Chain Antibody in Literature

1. Lan, Mingfu, et al. "Lambda light chain-restricted non-crystalline proximal tubulopathy with cast nephropathy in multiple myeloma: a case report and literature review." BMC nephrology 25.1 (2024): 324. https://doi.org/10.1186/s12882-024-03721-9

This article reports a rare case of IgD-λ multiple myeloma complicated with amorphous λ light chain proximal renal tubular lesions and light chain tubular nephropathy. Through clinicopathological analysis, its characteristics are explored to enhance the understanding of the diagnosis of this disease.

2. Rimsza, Lisa M., et al. "Kappa and lambda light chain mRNA in situ hybridization compared to flow cytometry and immunohistochemistry in B cell lymphomas." Diagnostic pathology 9.1 (2014): 144. https://doi.org/10.1186/1746-1596-9-144

This study evaluated the novel dual-color CISH technology, which can detect κ/LAMBDA light chain mRNA with high sensitivity. In the clonal assessment of B-cell lymphoma, it was highly consistent with the results of flow cytometry /IHC (with a coincidence rate of 98.6%), significantly enhancing the detection ability of light chains in tissue sections.

3. Guillory, Tesha, et al. "Hematogones With Lambda Light Chain Restriction in a 4-Year-Old Boy With Burkitt Lymphoma: A Potential Diagnostic Pitfall." Laboratory Medicine 47.2 (2016): 163-170. https://doi.org/10.1093/labmed/lmw009

This article reports a rare case: abnormal hematopoietic precursor cells (hematogones) appeared in the bone marrow of a 4-year-old child during treatment. Although they had a typical phenotype, they abnormally expressed λ light chain restriction, and molecular testing showed no clonicity, suggesting the need to be vigilant about potential misunderstandings in the assessment of B-cell lymphoma.

4. Raybould, Matthew IJ, et al. "Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profiling." Communications Biology 7.1 (2024): 62. https://doi.org/10.1038/s42003-023-05744-8

This study, through the analysis of the machine learning tool TAP, found that although the overall developability risk of λ light chain antibodies is higher than that of κ antibodies, a considerable number of λ antibodies still have a relatively low risk and can be used as high-quality candidate drugs. It is called for a rational increase in the diversity of λ antibodies in immunotherapy.

5. Berghaus, Natalie, et al. "Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement." PLoS One 17.2 (2022): e0264407. https://doi.org/10.1371/journal.pone.0264407

This study analyzed 85 patients with λ light amyloidosis and found that the type of organ involved was significantly associated with specific IGLV gene subtypes: the cardiodominant type was mostly associated with IGLV3-21, the kidney-dominant type was mostly associated with IGLV1-44, and the cardiorenal co-affected type was mainly associated with IGLV6-57.

Creative Biolabs: Lambda Light Chain Antibodies for Research

Creative Biolabs specializes in the production of high-quality Lambda Light Chain antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom Lambda Light Chain Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our Lambda Light Chain antibodies, custom preparations, or technical support, contact us at email.